Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Secukinumab.
- Who it may be relevant to
- Registry conditions: Hidradenitis Suppurativa (HS). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Real-World Evaluation of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa
Overview
This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.
Interventions
- Drug Secukinumab
secukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection
Primary outcome measures
- Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) [Time frame: From enrollment to the end of treatment at Week 12]
Secondary outcome measures (1)
- Dermatology Life Quality Index [Time frame: From enrollment to the end of treatment at week 12]
Eligibility criteria
Inclusion criteria
- age ≥18 years
- diagnosis of moderate-to-severe HS with Hurley stage II or III
- Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules
- inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors
Exclusion criteria
- active infections (e.g., viral hepatitis, active tuberculosis)
- use of other biologics or systemic immunosuppressants within the past three months
- severe organ dysfunction (e.g., hepatic or renal failure)
- any other conditions that might affect study results
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- No. 1 Shuai Fu Yuan, Dongcheng District, Beijing — Beijing
Identifiers
NCT: NCT07109765 · No. I-24PJ1844